96530-59-5

Basic information

• Product Name: 1-(4-Iodophenyl)piperazine
• Synonyms: 1-(piperazin-1-yl)-4-iodobenzene
• CAS NO: 96530-59-5
• Molecular Formula: C₁₀H₁₃IN₂
• Molecular Weight: 288.13
• Product Categories: pharmacetical;Organohalides
• Mol File: 96530-59-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 370.3 °C at 760 mmHg
• Flash Point: 177.8 °C
• Appearance: pale yellow solid
• Density: 1.602 g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.614
• CAS DataBase Reference: 1-(4-Iodophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Iodophenyl)piperazine(96530-59-5)
• EPA Substance Registry System: 1-(4-Iodophenyl)piperazine(96530-59-5)

Safety Data

• Hazardous Substances Data: 96530-59-5(Hazardous Substances Data)

Usage

General Description

1-(4-Iodophenyl)piperazine, also known as 4-IP, is a chemical compound that is commonly used in research and pharmaceutical applications. It is a derivative of piperazine and contains an iodine atom attached to a phenyl ring. 4-IP has been studied for its potential as an antipsychotic and anxiolytic agent, as well as its effects on serotonin and dopamine receptors in the brain. It has also been investigated for its potential role in the treatment of drug addiction and neurodegenerative disorders. Additionally, 4-IP has been used as a precursor in the synthesis of other pharmaceutical compounds. However, it is important to note that 4-IP is a controlled substance in some countries and is subject to regulations regarding its use and distribution.

InChI:InChI=1/C10H13IN2/c11-9-1-3-10(4-2-9)13-7-5-12-6-8-13/h1-4,12H,5-8H2

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 540-37-4 p-aminoiodobenzene 
• 92-54-6 4-phenyl-1-piperazine 

Downstream Products

• 158985-08-1 3-[4-(4-iodophenyl)-piperazin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine 
• 516472-87-0 1-[(S)-N-tert-butyloxycarbonyl-N-methyltyrosyl]-4-(4-iodophenyl)piperazine 
• 681482-18-8 t-butyl 4-([1,1′-biphenyl]-4-yl)piperazine-1-carboxylate 
• 1563174-98-0 t-butyl 4-(3′-methoxybiphenyl-4-yl)piperazine-1-carboxylate 
• 1563175-18-7 N6-(2-(4-(3′-methoxy[1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-5,6,7,8-tetrahydroquinazoline-2,6-diamine 

Relevant articles and documents

FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF

The invention relates to compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are defined herein, and to their use in a variety of biological imaging techniques and therapeutic methods. In aspects, the invention relates to conjugates comprising the compounds of formula I and their associated uses and therapeutic uses.

Cellular localisation of structurally diverse diphenylacetylene fluorophores

Fluorescent probes are increasingly used as reporter molecules in a wide variety of biophysical experiments, but when designing new compounds it can often be difficult to anticipate the effect that changing chemical structure can have on cellular localisa

Structural modifications of neuroprotective anti-parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6, 7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): An effort toward the improvement of in vivo efficacy of the parent molecule

In our overall goal to develop multifunctional dopamine D 2/D3 agonist drugs for the treatment of Parkinson's disease (PD), we previously synthesized potent D3 preferring agonist D-264 (1a), which exhibited neuroprotective properties in two animal models of PD. To enhance the in vivo efficacy of 1a, a structure-activity relationship study was carried out. Competitive binding and [35S]GTPγS functional assays identified compound (-)-9b as one of the lead molecules with preferential D3 agonist activity (EC50(GTPγS); D3 = 0.10 nM; D2/D3 (EC50): 159). Compounds (-)-9b and (-)-8b exhibited high in vivo activity in two PD animal models, reserpinized and 6-hydroxydopamine (OHDA)-induced unilateral lesioned rats. On the other hand, 1a failed to show any in vivo activity in these models unless the compound was dissolved in 5-10% beta-hydroxy propyl cyclodextrin solution. Lead compounds exhibited appreciable radical scavenging activity. In vitro experiments with dopaminergic MN9D cells indicated neuroprotection by both 1a and (-)-9b from toxicity of MPP+.